Cargando…

Gaps in hepatocellular carcinoma surveillance among insured patients with hepatitis B infection without cirrhosis in the United States

Suboptimal adherence to guidelines for hepatocellular carcinoma (HCC) surveillance among high‐risk patients is a persistent problem with substantial detriment to patient outcomes. While patients cite cost as a barrier to surveillance receipt, the financial burden they experience due to surveillance...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, Mindie H., Roberts, Lewis R., Engel‐Nitz, Nicole M., Bancroft, Tim, Ozbay, A. Burak, Singal, Amit G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9701467/
https://www.ncbi.nlm.nih.gov/pubmed/36178256
http://dx.doi.org/10.1002/hep4.2087
_version_ 1784839541578792960
author Nguyen, Mindie H.
Roberts, Lewis R.
Engel‐Nitz, Nicole M.
Bancroft, Tim
Ozbay, A. Burak
Singal, Amit G.
author_facet Nguyen, Mindie H.
Roberts, Lewis R.
Engel‐Nitz, Nicole M.
Bancroft, Tim
Ozbay, A. Burak
Singal, Amit G.
author_sort Nguyen, Mindie H.
collection PubMed
description Suboptimal adherence to guidelines for hepatocellular carcinoma (HCC) surveillance among high‐risk patients is a persistent problem with substantial detriment to patient outcomes. While patients cite cost as a barrier to surveillance receipt, the financial burden they experience due to surveillance has not been examined. We conducted a retrospective administrative claims study to assess HCC surveillance use and associated costs in a US cohort of insured patients without cirrhosis but with hepatitis B virus (HBV) infection, monitored in routine clinical practice. Of 6831 patients (1122 on antiviral treatment, 5709 untreated), only 39.3% and 51.3% had received any abdominal imaging after 6 and 12 months, respectively, and patients were up to date with HCC surveillance guidelines for only 28% of the follow‐up time. Completion of surveillance was substantially higher at 6 and 12 months among treated patients (51.7% and 69.6%, respectively) compared with untreated patients (36.9% and 47.6%, respectively) (p < 0.001). In adjusted models, treated patients were more likely than untreated patients to receive surveillance (hazard ratio [HR] 1.75, 95% confidence interval [CI] 1.53–2.01, p < 0.001), and the proportion of those up to date with surveillance was 9.7% higher (95% CI 6.26–13.07, p < 0.001). Mean total and patient‐paid daily surveillance‐related costs ranged from $99 (ultrasound) to $334 (magnetic resonance imaging), and mean annual patient costs due to lost productivity for surveillance‐related outpatient visits ranged from $93 (using the federal minimum wage) to $321 (using the Bureau of Labor Statistics wage). Conclusion: Use of current HCC surveillance strategies was low across patients with HBV infection, and surveillance was associated with substantial patient financial burden. These data highlight an urgent need for accessible and easy‐to‐implement surveillance strategies with sufficient sensitivity and specificity for early HCC detection.
format Online
Article
Text
id pubmed-9701467
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-97014672022-11-28 Gaps in hepatocellular carcinoma surveillance among insured patients with hepatitis B infection without cirrhosis in the United States Nguyen, Mindie H. Roberts, Lewis R. Engel‐Nitz, Nicole M. Bancroft, Tim Ozbay, A. Burak Singal, Amit G. Hepatol Commun Original Articles Suboptimal adherence to guidelines for hepatocellular carcinoma (HCC) surveillance among high‐risk patients is a persistent problem with substantial detriment to patient outcomes. While patients cite cost as a barrier to surveillance receipt, the financial burden they experience due to surveillance has not been examined. We conducted a retrospective administrative claims study to assess HCC surveillance use and associated costs in a US cohort of insured patients without cirrhosis but with hepatitis B virus (HBV) infection, monitored in routine clinical practice. Of 6831 patients (1122 on antiviral treatment, 5709 untreated), only 39.3% and 51.3% had received any abdominal imaging after 6 and 12 months, respectively, and patients were up to date with HCC surveillance guidelines for only 28% of the follow‐up time. Completion of surveillance was substantially higher at 6 and 12 months among treated patients (51.7% and 69.6%, respectively) compared with untreated patients (36.9% and 47.6%, respectively) (p < 0.001). In adjusted models, treated patients were more likely than untreated patients to receive surveillance (hazard ratio [HR] 1.75, 95% confidence interval [CI] 1.53–2.01, p < 0.001), and the proportion of those up to date with surveillance was 9.7% higher (95% CI 6.26–13.07, p < 0.001). Mean total and patient‐paid daily surveillance‐related costs ranged from $99 (ultrasound) to $334 (magnetic resonance imaging), and mean annual patient costs due to lost productivity for surveillance‐related outpatient visits ranged from $93 (using the federal minimum wage) to $321 (using the Bureau of Labor Statistics wage). Conclusion: Use of current HCC surveillance strategies was low across patients with HBV infection, and surveillance was associated with substantial patient financial burden. These data highlight an urgent need for accessible and easy‐to‐implement surveillance strategies with sufficient sensitivity and specificity for early HCC detection. John Wiley and Sons Inc. 2022-09-30 /pmc/articles/PMC9701467/ /pubmed/36178256 http://dx.doi.org/10.1002/hep4.2087 Text en © 2022 The Authors. Hepatology Communications published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Articles
Nguyen, Mindie H.
Roberts, Lewis R.
Engel‐Nitz, Nicole M.
Bancroft, Tim
Ozbay, A. Burak
Singal, Amit G.
Gaps in hepatocellular carcinoma surveillance among insured patients with hepatitis B infection without cirrhosis in the United States
title Gaps in hepatocellular carcinoma surveillance among insured patients with hepatitis B infection without cirrhosis in the United States
title_full Gaps in hepatocellular carcinoma surveillance among insured patients with hepatitis B infection without cirrhosis in the United States
title_fullStr Gaps in hepatocellular carcinoma surveillance among insured patients with hepatitis B infection without cirrhosis in the United States
title_full_unstemmed Gaps in hepatocellular carcinoma surveillance among insured patients with hepatitis B infection without cirrhosis in the United States
title_short Gaps in hepatocellular carcinoma surveillance among insured patients with hepatitis B infection without cirrhosis in the United States
title_sort gaps in hepatocellular carcinoma surveillance among insured patients with hepatitis b infection without cirrhosis in the united states
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9701467/
https://www.ncbi.nlm.nih.gov/pubmed/36178256
http://dx.doi.org/10.1002/hep4.2087
work_keys_str_mv AT nguyenmindieh gapsinhepatocellularcarcinomasurveillanceamonginsuredpatientswithhepatitisbinfectionwithoutcirrhosisintheunitedstates
AT robertslewisr gapsinhepatocellularcarcinomasurveillanceamonginsuredpatientswithhepatitisbinfectionwithoutcirrhosisintheunitedstates
AT engelnitznicolem gapsinhepatocellularcarcinomasurveillanceamonginsuredpatientswithhepatitisbinfectionwithoutcirrhosisintheunitedstates
AT bancrofttim gapsinhepatocellularcarcinomasurveillanceamonginsuredpatientswithhepatitisbinfectionwithoutcirrhosisintheunitedstates
AT ozbayaburak gapsinhepatocellularcarcinomasurveillanceamonginsuredpatientswithhepatitisbinfectionwithoutcirrhosisintheunitedstates
AT singalamitg gapsinhepatocellularcarcinomasurveillanceamonginsuredpatientswithhepatitisbinfectionwithoutcirrhosisintheunitedstates